Tonix Pharmaceuticals Holding Corp. disclosed preliminary operating results for the quarter ended September 30, 2026. The company estimated net revenue from its product TONMYA to be between $14.0 million and $15.0 million. As of the end of the quarter, Tonix reported cash and cash equivalents of approximately $162.8 million. These figures are preliminary estimates subject to revision upon completion of financial closing procedures and should not be regarded as a representation of actual results. Tonix Pharmaceuticals Holding Corp. operates in the biopharmaceutical industry, focusing on the development and commercialization of immunotherapies.
